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Abstract
Objective This study is a pharmacogenetic clinical trial
designed to clarify whether the N-acetyltransferase 2 gene
(NAT2) genotype-guided dosing of isoniazid improves the
tolerability and efficacy of the 6-month four-drug standard
regimen for newly diagnosed pulmonary tuberculosis.
Methods In a multicenter, parallel, randomized, and controlled
trial with a PROBE design, patients were assigned to either
conventional standard treatment (STD-treatment: approx.
5 mg/kg of isoniazid for all) or NAT2 genotype-guided
treatment (PGx-treatment: approx. 7.5 mg/kg for patients
homozygous for NAT2*4: rapid acetylators; 5 mg/kg,
patients heterozygous for NAT2*4: intermediate acetylators;
2.5 mg/kg, patients without NAT2*4: slow acetylators). The
primary outcome included incidences of 1) isoniazid-related
liver injury (INH-DILI) during the first 8 weeks of therapy,
and 2) early treatment failure as indicated by a persistent
positive culture or no improvement in chest radiographs at
the8th week.
Results One hundred and seventy-two Japanese patients
(slow acetylators, 9.3 %; rapid acetylators, 53.5 %) were
enrolled in this trial. In the intention-to-treat (ITT) analysis,
INH-DILI occurred in 78 % of the slow acetylators in the
STD-treatment, while none of the slow acetylators in the
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PGx-treatment experienced either INH-DILI or early treat-
ment failure. Among the rapid acetylators, early treatment
failure was observed with a significantly lower incidence
rate in the PGx-treatment than in the STD-treatment (15.0 %
vs. 38 %). Thus, the NAT2 genotype-guided regimen
resulted in much lower incidences of unfavorable events,
INH-DILI or early treatment failure, than the conventional
standard regimen.
Conclusion Our results clearly indicate a great potential of
the NAT2 genotype-guided dosing stratification of isoniazid
in chemotherapy for tuberculosis.
Keywords ArylamineN-acetyltransferase 2 (NAT2) .
Isoniazid . Pulmonary tuberculosis . Pharmacogenomics .
Randomized clinical trial
Introduction
The annual incidence of tuberculosis is still over nine
million cases worldwide [1]. With supervision by The
Stop TB Strategy, the World Health Organization (WHO)
has pursued standardized treatments [2]. The most effec-
tive treatment has been a standard 6-month four-drug
regimen for the initial treatment of drug-susceptible pul-
monary tuberculosis [3, 4]. However, several drug-related
adverse reactions can result in discontinuation of the treat-
ment [4, 5]. There can also be considerable morbidity,
even mortality, particularly with drug-induced liver injury
(DILI) [6–8]. These events incur substantial additional
costs because of the increased frequency of outpatient
visits, laboratory tests, and hospitalization in more serious
instances. Alternative agents can have greater problems
with toxicity and are often less effective, and treatment
could be prolonged despite attendant challenges to ensure
compliance. As a result, the risk of treatment failure and
relapse would become even higher. Therefore, individual-
ized drug management using four standard drugs to min-
imize the incidence of adverse drug reactions is an unmet
need in the present clinical circumstances.
Isoniazid (INH), a key drug of the currently recommen-
ded regimen for patients with tuberculosis, is metabolized
by genetically polymorphic N-acetyltransferase 2 (NAT2)
[9–11]. The rate of elimination of INH is trimodally distrib-
uted in accordance with NAT2 metabolic activity [12, 13];
NAT2 activity status is genetically controlled and basically
depends on the number of active alleles (NAT2*4 and *12).
Previous findings indicate that a genetic polymorphism
is associated with large interindividual differences in the
toxicity and efficacy of INH [13–19]. Slow acetylators,
patients without any active alleles, develop hepatotoxic-
ity more often than rapid acetylators, patients with two
active alleles, during treatment for tuberculosis with the
standard regimen [18, 19]. In contrast, rapid acetylators
are prone to treatment failure with the standard regimen
[13–16], probably due to insufficient exposure to INH.
These observations imply that current dosage of INH
recommended internationally is too much for slow ace-
tylators and insufficient for rapid acetylators. Thus, we
should assume that pharmacogenetically stratified treat-
ment has the potential to avoid unfavorable outcomes with
improvements in the cure rate.
Before the start of a prospective clinical trial with the
NAT2 genotype-guided regimen, dose-finding pharmaco-
kinetic studies were independently carried out in Europe
and Japan to expect appropriate clinical dosages of INH
for each NAT2 genotype [20, 21]. Based on pharmaco-
kinetic parameters estimated from these dose-finding
studies, a genotype-based dosage for the present study
was determined as follows; half the standard INH dose
for slow acetylators, 1.5 times the standard dose for
rapid acetylators, and the standard dose for intermediate
acetylators.
Here, we report outcomes of a randomized controlled
trial for pharmacogenetics-based tuberculosis therapy (RT-
PGTT) conducted in Japan (ClinicalTrials.gov Identifier:
NCT 00298870). The purpose of this study was to elu-
cidate whether stratified medicine based on the NAT2
gene polymorphism could improve the tolerability and




This study was designed as a multicenter, two-treatment,
parallel group, prospective, randomized, open-label,
blinded-endpoint (PROBE) controlled trial, comparing
NAT2 genotype-guided and standard dosing of isoniazid in
the intensive phase of the 6-month four-drug standard treat-
ment for patients with newly diagnosed pulmonary tubercu-
losis. This study was approved by the Institutional Review
Boards of Osaka University and the participating hospitals,
and has been registered on ClinicalTrials.gov. The participat-
ing hospitals were National Hospital Organization Toneyama
National Hospital, Osaka Prefectural Hospital Organiza-
tion Osaka Prefectural Medical Center for Respiratory and
Allergic Diseases, National Hospital Organization Kinki-
Chuo Chest Medical Center, and Japan Anti-Tuberculosis As-
sociation Osaka Hospital, all in Osaka, Japan. This study was
conducted according to the principles of the Declaration of
Helsinki and in compliance with applicable regulatory
requests. All of the patients being tested gave written informed
consent before the study.
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Study population
The eligible population was identified from a series of
patients newly diagnosed with pulmonary tuberculosis
(men and women, 20–75 years old), requiring the 6-
month four-drug standard treatment for the first time.
The exclusion criteria in the pre-study screening phase
were as follows: abnormal test results for liver and kidney
function (serum aspartate aminotransferase; AST>45 (IU/L),
alanine aminotransferase; ALT>50 (IU/L), alkaline phospha-
tise; ALP>444 (IU/L), total bilirubin>1.6 (mg/dL), and creat-
inine>1.4 (mg/dL)) before the study treatments commenced,
long-term use of steroids and/or immunosuppressants, inade-
quate clinical conditions such as hyperglycemia diabetes mel-
litus, acute life-threatening chronic progressive disease,
pregnancy or lactation, and alcoholism. Patients not expected
to complete the study protocol for social reasons were not
recruited.
After the allocation of the patients,Mycobacterium avium
complex (MAC) infection and resistance to INH were ex-
amined and used as additional exclusion criteria to ensure
the efficacy of INH. Patients with complex infections or
INH resistance were excluded from the final analysis as
illustrated in Fig. 1.
Randomization and study medication
Before the allocation of a consenting patient, an individ-
ual NAT2 genotype status was determined at the central
laboratory and office in parallel with clinical pre-study
screening at each site. Qualified patients were assigned
randomly to the pharmacogenetic-guided treatment (PGx-
treatment) or the conventional standard treatment (STD-
treatment) according to a computer-generated dynamic
randomization schedule, which minimized the imbalance
of patient backgrounds including NAT2 genotype status
(rapid-, intermediate-, and slow-acetylator genotypes), study
site, bodyweight, age, and baselineγ-glutamyltranspeptidase.
Within 72 h after a blood sample was drawn for geno-
typing, site investigators were informed of only the dose
of INH assigned to each patient (see Table 1). INH
dosage for patients with more than 80 kg in body
weight was not set up, in consideration for average body sizes
of the Japanese population. The allocation and NAT2 genotype
- Non-tuberculosis   
Micobacterium infection
- INH-resistant 
Provided informed consents for the study  (n=173)
NAT2 genotyping
(at a central laboratory)
Screening test 
(at each hospital laboratory as routine)
Ineligible  (n=1)
Computer generated randomized dynamic allocation
SA-type IA-type RA-type
PGx
High-doseSt-dose Low-dose Middle (St)-dose St-dose
n=43
Informed only assigned dose of INH to investigators
STD PGx/STD PGx STD
Valid for INH-DILI
Valid for






Fig. 1 Trial profile.
Abbreviations: RA-type, rapid
acetylator genotype homozygous
for NAT2*4; IA-type, intermedi-
ate acetylator genotypes hetero-
zygous for NAT2*4; SA-type,
slow acetylator genotypes
without NAT2*4; PGx, NAT2
genotype-guided treatment in
which INH dosage was pharma-




dosage for all; Low-dose, half
the conventional standard dose;




injury associated with isoniazid
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status of patients were semi-concealed from all clinical staff
and patients.
In this trial, all patients were treated according to the Japan
Anti-Tuberculosis Association (JATA)’s guideline with the
exception of INH dosage; a 6-month regimen comprising
INH, rifampicin, pyrazinamide, and ethambutol/streptomycin
for the first 2 months followed by rifampicin and INH for 4
months. This treatment schedule is in line with the current
standard treatment recommended internationally for adult res-
piratory tuberculosis [4].
Table 1 summarizes the assigned dose of INH for each
parallel group. All patients started taking the standard
oral dose (approx. 5 mg/kg b.w., once daily) throughout
the course so as to avoid delay in initial treatment, which
was the same dosing for the STD-treatment. For patients
in the PGx-treatment, dosages were adjusted based on
individual NAT2 status within 3 days. Modified daily
INH doses were approximately 7.5, 5 and 2.5 mg/kg
for rapid, intermediate and slow acetylators, respectively.
Approximately 5 mg/kg of INH, as same as the standard
dose, was given to all of the intermediate acetylators
throughout. Regarding the other drugs for the standard
regimen, standard daily doses of rifampicin (10 mg/kg,
max. 600 mg/body), pyrazinamide (25 mg/kg, 1,500 mg/
body), ethambutol (15 (20) mg/kg, 750 (1,000) mg/
body), and streptomycin (15 mg/kg, 750 mg/body) were
recommended with the following dose ranges allowed at
the discretion of the physician in charge of treatment: ri-
fampicin, 8–12 mg/kg; pyrazinamide, 20–30 mg/kg; etham-
butol, 15–20 mg/kg; streptomycin, 12–18 mg/kg.
Administration of vitamin B6 was also allowed at the discre-
tion of the physician. Primary outcomes were evaluated at the
8th week. The same treatments continued for 6 months in both
groups if patients did not have any clinical need to change the
ongoing treatment.
Study procedures
The baseline clinical assessment consisted of chest radiogra-
phy, demographics (age, sex, body weight, and body height),
sputum examinations, and serum biochemistry tests. Three
consecutive sputum samples were collected for detection of
M. tuberculosis which was performed by microscopy, culture
and polymerase chain reaction (PCR) assay, and for suscepti-
bility testing ofM. tuberculosis to INH, rifampicin, ethambutol
and pyrazinamide. A blood sample was drawn to determine
serum concentrations of ALT, AST, ALP, bilirubin, creatinine,
γ-glutamyltranspeptidase, albumin, C-reactive protein, and
glucose, a full blood count, and the erythrocyte sedimentation
rate. Sputum and blood samples were collected from all the
patients to analyze the items above at weeks 1, 2, 3, 4, 6, and
8 during the intensive phase, and then monthly during the
continuation phase for 6 months. At each point, patients were
asked about any adverse events that might have occurred since
the last point. Chest radiographs were taken at the 8th week,
and the 24th week or the end of treatment.
Outcome measures and assessments
The primary outcome measures were the incidences of un-
favorable events in two different treatment regimens in
population who required dose modification based on the
NAT2 gene polymorphism: (1) the incidences of drug–in-
duced liver injury associated with INH (INH-DILI) that oc-
curred within 8 weeks of the treatments, and (2) the incidences
of early treatment failure at the 8th week. The secondary
outcome measures were other adverse events observed during
the 8-week study period.
INH-DILI was assessed according to the diagnostic criteria
of the Manual for Serious Side-Effects of Drug-induced Liver
Injury from the Ministry of Health, Labor and Welfare of
Japan [22–24]. In brief, hepatocellular injury was defined as
a more than two-fold increase in the upper limit of the normal
(ULN) concentration of ALT alone or a serum ALT ratio/ALP
ratio greater than 5, where the ALT ratio0ALT value/ULN of
ALT, and ALP ratio0ALP value/ULN of ALP. Cholestatic
injury was defined as an increase above two-fold of the upper
limit of the normal range of ALP or a serum ALT ratio/ALP
ratio less than 2. Mixed injury was defined as a serum ALT
ratio/ALP ratio of between 2 and 5. Causality assessments
showed a relationship to the INH administration if the total
score was more than grade 3, i.e. ‘possible’.
Early treatment failure was defined as a combined surro-
gate endpoint: (1) a positive sputum culture at the 8th week
examination, or (2) no sign of improvement in the chest
radiograph at 8 weeks for patients with a negative sputum
culture at baseline. Secondary outcome measure was defined
by the other adverse events during the 8 weeks of the intensive
phase of the anti-tuberculosis therapy.
Table 1 Dose of isoniazid in NAT2-genotype-guided treatment or
conventional standard treatment
NAT2 status SA-type IA-type RA-type
Body weight (kg) <40 40≤ <40 40≤ <40 40≤
Dose of isoniazid (mg, once a day)
PGx-treatment 100 150 200 300 300 450
STD-treatment 200 300a 200 300a 200 300a
Isoniazid tablet (100 mg, 50 mg) was used practically. Stratified dose
was 2.5, 5, 7.5 mg/kg b. w. for patients with SA-, IA-, and RA-type,
respectively. SA-type, slow acetylator genotypes without NAT2*4; IA-
type, intermediate acetylator genotypes heterozygous for NAT2*4;
RAtype, rapid acetylator genotype homozygous for NAT2*4. PGx-
treatment, NAT2-genotype guided treatment; STD-treatment, conven-
tional standard treatment.
aMaximum dose regardless of body weight according to guidelines of
ATS and JATA
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All outcomes were determined by the members of a
separate central end point adjudication committee who used
standard definitions and were unaware of treatment alloca-
tion and NAT2 genotypes. An independent Data and Safety
Monitoring Committee could advise early termination of the
trial for safety, scientific or ethical reasons.
NAT2 genotyping
Genomic DNAwas extracted from peripheral whole blood of
each subject using a QIA amp BloodMini Kit (QIAGEN). Six
single nucleotide polymorphisms in the NAT2 gene were
analyzed: 190C to T (NAT2*19), 191 G to A (NAT2*14),
341 T to C (NAT2*5), 481C to T, 590 G to A (NAT2*6),
and 857 G to A (NAT2*7). Detections were separately dupli-
cated for quality control of genotyping. In brief, the three
mutations 481C to T, 590 G toA and 857 G toAwere detected
by a PCR-RFLP (restriction fragment length polymorphism)
method as described previously [17]. After PCR amplification
using specific primers, the PCR products were digested with
the restriction enzymes Kpn I, Taq I, and BamHI to determine
the nucleotide substitution at 481, 590, and 857, respectively.
A mismatch PCR-RFLP procedure was performed to detect
the 341 T to C, 190C to T and 191 G to A substitutions, as
described previously [20]. The restriction enzymes Dde I and
Msp I were used for the PCR products to determine the
nucleotide substitutions at 341 and 190/191, respectively.
Alleles without any defective forms were defined as function-
al allele, NAT2*4.
Sample size calculation
On the basis of data from our previous study [18, 25], we
assumed that the incidence of INH-induced liver injury in
slow acetylators would be 65 % in the control arm (STD-
treatment; conventional standard dosing of INH) and 15 %
in the test arm (PGx-treatment; NAT2 genotype-guided dos-
ing of INH). We hypothesized that the occurrence of early
therapeutic failure in rapid acetylators would be decreased,
from 35 % in the STD-treatment to 15 % in the PGx-
treatment [26]. To achieve a power of 0.8 with an alpha of
0.05, we aimed to enroll 22 slow acetylators and 156 evalu-
able rapid acetylators in the trial. According to our calcu-
lations, a maximum sample size of 360 patients would be
needed to test this hypothesis, allowing for a 15 % dropout
rate, with frequencies of rapid, intermediate and slow ace-
tylators estimated at 0.50, 0.42 and 0.08, respectively. A
group sequential analysis would be performed if 16 slow
acetylators were assessable. The enrollment would be
stopped when p values regarding INH-DILI in slow acety-
lators were less than O’Brien-Fleming type stopping bound-
ary determined by Lan-DeMets approach. Then, the trial
would be finalized early because of ethical considerations.
Statistical analysis
The analyses were based on the intention-to-treat ap-
proach, including all assessable randomized patients.
Since the patients with intermediate genotypes receive
the same dose of INH irrespective of the results of the
randomization, their data were analyzed as a combined
group. A two-tailed significance test was used. Categor-
ical data were compared using the χ2 test or Fisher’s
exact test as appropriate and Cochran-Mantel-Haenszel
test was used for multivariate analyses. Continuous var-
iables are presented as the mean and standard deviation
(SD) or 25 %, 50 % and 75 % percentiles as applicable
and were analyzed by ANOVA with posthoc and the
Student-t test (for parametric variables) and the Mann-
Whitney U test (for non-parametric variables). The Lan-
DeMets alpha spending function was employed for ma-
jor outcomes. Multivariable logistic analyses were per-
formed to evaluate the relationship between the incidence of
unfavorable events and the baseline factors/covariates.
Analyses were performed using SPSS ver. 11.0 (SPSS
Inc.) and R ver. 2.10.1 (The R Foundation for Statistical
Computing).
Results
Patient enrollment and demographics
In all, 172 patients were randomly assigned to one of the
two study regimens, the NAT2 genotype-guided dosing
treatment (PGx-treatment) and the conventional standard
dosing treatment (STD-treatment), as summarized in Fig. 1.
The patients’ backgrounds showed a balanced distribution
(Table 2). Eighty three patients were assigned to the PGx-
guided therapy and 89 to the empirical therapy. Among them,
17 patients were not eligible for analysis since they met
exclusion criteria after their allocation; 12 with primary
INH-resistant tuberculosis and five with MAC infections.
The rest of the 155 patients were infected with organisms
sensitive to all first-line anti-TB drugs. The distribution of
NAT2 genotype frequencies was similar to that in our previous
study [18].
Primary Outcomes
Drug-induced liver injury associated with isoniazid
(INH-DILI)
Seven of nine slow acetylators in the STD-treatment expe-
rienced INH-related liver injury (INH-DILI) within the first
4 weeks, while none of the seven slow acetylators in the
PGx-treatment did during the first 8 weeks (attribute risk
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difference; 77.8 %, p00.003, Table 3a). Conversely, few
rapid acetylators in either group had INH-DILI during
the first 8 weeks; 4.2 % (2/48 patients) in the STD-
treatment and 4.6 % (2/44 patients) in the PGx-
treatment receiving high-dose INH, which were impor-
tantly equivalent to the incidence in intermediate acety-
lators (4.7 %, 3/64 patients). These outcomes were not
different in a population valid for early treatment failure.
Multivariable logistic analysis using the baseline patient
characteristics revealed that the NAT2 slow acetylator
genotype was associated with INH-DILI in the STD-
treatment, but not in the PGx-treatment at all, suggesting
standard dose of INH is too much for slow acetylators.
There was not any other factors and confounders associated
with INH-DILI.
Early treatment failure
The therapeutic effects of NAT2 genotype-guided dosing on
early treatment failure against drug-sensitive tuberculosis are
shown in Table 3b). The NAT2 genotype-guided regimen
successfully reduced the incidence of early treatment failure
in rapid acetylators; 15.0 % (6/40 patients) in the PGx-
treatment and 39.5 % (17/43 patients) in the STD-treatment
(relative risk; 0.379 [95 % CI: 0.116, 0.866], p00.013). The
difference was distinct on multivariate analysis stratified by
high-excretion level of tubercle bacilli (Pooled odds ratio;
0.274 [95%CI: 0.097, 0.776], p00.015). One rapid acetylator
in the STD-treatment who developed INH-DILI failed to
achieve any clinical improvement by the 8th week of treat-
ment. Importantly, two of nine (22.2 %) slow acetylators with
Table 2 Baseline characteristics of all randomized participants valid for evaluation of isoniazid-related liver injury and other adverse events on
intention-to-treat bases
Parameters NAT2 genotype status SA-type IA-type RA-type p value
Treatments STD PGx PGx/STD PGx STD
Patients (n) 9 7 64 44 48
Sex (M/F, n) 4/5 4/3 44/20 25/19 35/13
Age (years)a 35.0 48.0 48.5 50.5 51.0 0.614
(35.0–43.0) (36.0–58.0) (34.0, 60.0) (33.0, 57.8) (30.0, 60.2)
Weight (kg)a 55.0 59.5 54.1 50.0 57.5 0.058
(52.8–59.8) (47.9–62.8) (50.1–62.2) (45.9–55.2) (47.6–63.8)
AST (IU/L)a 18 17 18 16 19 0.165
(15–22) (17–27) (15–24) (13–20) (15–22)
ALT (IU/L)a 12 15 14 12 15 0.066
(10–19) (9–24) (10–21) (8–16) (11–21)
ALP (IU/L)a 241 244 238 255 242 0.696
(214–305) (195–329) (184–285) (208–304) (205–288)
Total-bilirubin (mg/dL)a 0.3 0.5 0.6 0.5 0.6 0.338
(0.3–0.6) (0.5–0.8) (0.4–0.7) (0.4–0.6) (0.4–0.7)
Creatinine (mg/dL)a 0.6 0.6 0.7 0.7 0.7 0.462
(0.5–0.7) (0.5–0.8) (0.6–0.8) (0.5–0.8) (0.6–0.8)
Anti-tuberculosis drugs (Dose, mg/kg/day)b
Isoniazidb 5.5 (0.8) 2.6 (0.3) 5.5 (0.9) 8.8 (1.3) 5.5 (1.0) NA
Rifampicinb 8.7 (1.4) 8.9 (1.7) 8.7 (1.4) 9.5 (1.4) 9.4 (1.5) 0.076
Pyrazinamideb 23.7 (3.0) 20.7 (4.3) 22.1 (5.9) 22.7 (2.7) 22.8 (4.6) 0.676
Ethambutolb 14.5 (2.0) 15.4 (3.2) 14.4 (3.5) 15.4 (2.5) 15.3 (4.1) 0.555
Concomitant drug (%)
Vitamin B6 44.4 50.0 40.6 43.2 43.8
Primary sputum culture (n) of complex infection or INH resistance
Negative 1 0 21 8 8
Positive-low (< +++) 7 6 26 22 26
Positive-high (>0+++) 1 1 9 9 10
a Data are presented as the median (25 %, 75 %).
b Data are presented as means (SD).
There was no statistical difference between PGx and STD in IA. Five groups were compared by ANOVA. PGx, NAT2 genotype-guided treatment
group; STD, conventional standard treatment group; RA-type, rapid acetylator genotype homozygous for NAT2*4; IA-type, intermediate acetylator
genotypes heterozygous for NAT2*4; SA-type, slow acetylator genotypes without NAT2*4. NA, not applied
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INH-DILI in the STD-treatment (5 mg/kg) did not show any
clinical improvement. In these cases, their standard treatment
was interrupted due to the INH-DILI and it was inevitable to
withdraw INH for one of them. In contrast, all the slow
acetylators in the PGx-treatment achieved 8 weeks of treat-
ment successfully, even with a lower dose of isoniazid than in
convention therapy.
Combined unfavorable events
The incidence of combined unfavorable events, defined by
early therapeutic failure or INH-related drug-induced liver
injury, was significantly lower in the combined population
of rapid and slow acetylators; 17.0 % in the PGx-treatment
and 48.1% in the STD-treatment (relative risk; 0.354 [95%CI:
0.177, 0.707], p00.001 (Table 3c)). Furthermore, the risk
reduction was more conspicuous when the subjects were
stratified by the level of primary sputum culture; pooled odds
ratios [95%CI] were 0.229 [0.091, 0.548] in combined popu-
lation of rapid and slow acetylators.
Although the dose of INH for intermediate acetylators in the
PGx-treatment was the same as that in the STD-treatment,
overall clinical usefulness of the PGx-guided therapy was
compared with the empirical therapy: the combined unfavor-
able events were 20.5 % (16/78 patients) in PGx-guided
therapy and 42.9 % (33/77 patients) in the empirical therapy
(relative risk; 0.479 [95%CI: 0.288, 0.795], p00.003) (Fig. 2).
Sub-analyses
The cumulative incidence of INH-DILI over time is illustrated
in Fig. 3. Mean (SD) time to detect INH-DILI was 15.6 (6.9)
days in slow acetylators receiving the conventional standard
treatment. As for intermediate acetylators, INH-DILI, early
therapeutic failure and the combined unfavorable events oc-
curred in 4.7 % (3/64 patients), 26.8 % (15/56 patients) and
28.6 % (16/56 patients), respectively. Overall probabilities of
Table 3 Primary end point results in slow and rapid acetylator genotypes
NAT2 genotype status Groups (n) Incidence (%) Univariate Multivariate e
p values Relative risk (95 % CI) p values Pooled odds ratios (95 % CI)
a) Isoniazid-related liver injury
SA-type PGx (7) 0.0 0.003a – NAd
STD (9) 77.8
RA-typec PGx (44) 4.5 1.000 1.091 (0.160–7.42) NAd
STD (48) 4.2 reference
b) Early treatment failure
SA-type c PGx (7) 0.0 0.475 – – 0.595 – –
STD (9) 22.2
RA-type PGx (40) 15.0 0.013b 0.379 (0.166–0.866) 0.015b 0.274 (0.097–0.776)
STD (43) 39.5 reference reference
c) Unfavorable event, i.e., combined endpoints of isoniazid-related liver injury or early treatment failure
RA+SA-type PGx (47) 17.0 0.001a 0.354 (0.177–0.707) 0.002a 0.229 (0.091–0.574)
STD (52) 48.1 reference reference
PGx=NAT2 genotype-guided dosing group, STD=Conventional standard dosing group
a less than O’Brien-Fleming type stopping boundaries of the Lan-DeMets alpha spending function
b less than Pocock type stopping boundaries
c secondary end point of each NAT2 genotype status
d not applied because of no confounder, and












Fig. 2 Overall incidence of combined unfavorable events in the
patients who received PGx-therapy and in those who received empir-
ical therapy
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the combined unfavorable events were 23.3 % (24/103
patients) in the PGx-treatment (8/47 patients) plus intermedi-
ate acetylators (16/56 patients) and 48.1 % (25/52 patients) in
the STD-treatment.
Further explorative analyses were performed in 118
patients presenting as sputum culture-positive at screening,
who were infected with M. tuberculosis sensitive to first-
line anti-tuberculosis drugs. As well as primary outcomes,
PGx-guided treatment reduced INH-DILI with keeping
enough therapeutic efficacies in slow acetylators, and also
reduced incidence of persistent positive culture without
increase of INH-DILI frequency in rapid acetylators
(Fig. 4). Regarding persistent positive sputum culture at
the 8th week, the risk difference was striking in rapid
acetylators with highly-positive level of organisms on
primary sputum culture; 10.0 % (1/10 patients) in the
PGx-treatment and 66.7 % (6/9 patients) in the STD-
treatment (p00.020). Incidence of unfavorable events of
the combined population of rapid and slow acetylators
was obviously higher in the STD-treatment than in PGx-
treatment. In contrast, the PGx-guided dose stratification
reduced unfavorable events to the level of intermediate
acetylators’ (Fig. 5).
Secondary outcomes
Other adverse events observed during the 8-week study
period were skin and subcutaneous tissue disorders includ-
ing rashes (n048), nervous system disorders including
headaches (n022), gastrointestinal disorders (n022), pe-
ripheral neuropathy (n013), visual impediment (n03), and
hearing impairment (n03). Peripheral neuropathy was
observed in two of nine slow acetylators in the STD-
treatment, but not at all in the PGx-treatment (22 % vs
0 %). As for the other genotypes, peripheral neuropathy
was observed in four of 48 patients who received the
STD-treatment and three of 44 patients who received the
PGx-treatment (8 % vs 7 %) in the group of rapid acetyla-
tors, and four of 64 (6 %) in the group of intermediate
acetylators. Among the 13 patients presenting with this
event, seven patients received vitamin B6: one slow



















Fig. 3 Cumulative incidence curves of isoniazid related drug-induced
liver injury (INH-DILI) over time among the 172 patients. RA-type,
rapid acetylator genotype; IA-type, intermediate acetylator genotypes;
























Persistent positive culture 
Fig. 4 Incidence of isoniazid induced liver injury (INH-DILI) and per-
sistent positive culture among the patients with drug sensitive tuberculosis
on sputum culture at screening. Closed columns, INH-DILI; open col-
umns, persistent positive culture; RA-type, rapid acetylator genotype; IA-
type, intermediate acetylator genotypes; SA-type, slow acetylator geno-



















Fig. 5 Incidence of combined unfavorable events among the patients
with drug sensitive tuberculosis on sputum culture at screening. RA+
IA-type, combined with rapid or slow acetylator genotypes; IA-type,
intermediate acetylator genotypes; PGx, PGx-guided treatment; STD,
conventional standard-treatment
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treatment, one rapid acetylator in the PGx-treatment,
and three intermediate acetylators. There was no statisti-
cally significant difference in the incidence of these adverse
events between the PGx-treatment group and STD-treatment
group.
Discussion
In the present study we have demonstrated the significant
therapeutic potential of the NAT2 genotype-guided dosing
of INH in the intensive phase of the internationally stan-
dardized 6-month four-drug regimen for newly diagnosed
pulmonary tuberculosis. The new dosing regimen signifi-
cantly reduced the incidences of INH-DILI and early
treatment failure, compared to the conventional standard-
ized regimen. The slow acetylators assigned to the PGx-
treatment, who were administered a lower dose of INH
than the STD-treatment, developed no INH-related liver
injury, but achieved clinical improvements within 8 weeks.
On the other hand, the rapid acetylators in the PGx-
treatment, receiving a higher dose of INH, achieved a 25 %
higher rate of clinical improvement by the 8th week than
those in the STD-treatment, with an incidence of INH-related
liver injury of less than 5 %. The absolute risk reduction in
the combined population of rapid and slow acetylators was
31 % with respect to unfavorable events, i.e., INH-DILI or
early treatment failure.
NAT2 genotypic status has been focused on as a genomic
biomarker for individualized medicine to preempt INH-
related unfavorable events. In fact, INH-induced hepatotox-
icity has been studied enthusiastically worldwide since we
reported its association with slow acetylator genotypes [18].
In accordance with previous observational studies [18, 19],
the present randomized clinical trial has confirmed that slow
acetylators are prone to INH-DILI by conventional standard
treatment with the relative risk of 4.5 (95 % CI, 1.3–15.3).
Importantly, the present trial has clearly demonstrated
that the incidence of INH-DILI was strikingly decreased
by the NAT2-guided dosing stratification of INH. These
results suggest that NAT2-guided dosing for slow acetylators
would contribute to the preemptive discontinuation of anti-
tuberculous drugs, thereby reducing the incidence of treatment
failure and/or relapse of tuberculosis.
It has also been discussed that rapid acetylators are prone
to treatment failure during anti-tuberculosis therapy based
on INH [13, 15, 16]. Consistent with this, we showed that
the risk of treatment failure was higher in genotypic rapid
acetylators, treated with the conventional dosage of INH, in
the present study. Accumulating evidence has revealed the
mechanisms of treatment failure with the four-drug standard
regimen. Patients with low INH plasma concentrations have
a propensity for treatment failure or early relapse of
tuberculosis [27–29]. Indeed, in vitro and in vivo animal
studies have demonstrated that the cumulative antibacterial
effect of INH is associated with the area under the INH
concentration versus time curve [30]. In combination thera-
py for tuberculosis, the main population of M. tuberculosis
is susceptible to INH, while pyrazinamide is effective
against slower growing bacilli in acidic milieus, and rifam-
picin against nonreplicating bacilli. During the first 2 to
5 days of the multidrug therapy, the bactericidal activity is
derived mainly from INH [31, 32]. This bactericidal activity
ceases due to the emergence of an INH-resistant population
[33], resulting in treatment failure. In the present study,
NAT2 genotype-guided dosing stratification of INH obvi-
ously improves therapeutic efficacy against INH-sensitive
tuberculosis during the first 8 weeks, although the PGx-
treatment could not start until a couple of days after the first
dose. This fact strongly indicates that appropriate dose ad-
justment of INH at the beginning of therapy is important to
avoid treatment failure and the relapse of tuberculosis, es-
pecially for patients infected with M. tubeculusosis sensitive
to INH.
Of note, the success rate for anti-tuberculosis treatment
has been lower in Japan than in Western countries [1, 34].
Although a Japanese authority, JATA, has been propelling
WHO-recommended programs, and has changed the stan-
dard INH dose from 400–450 mg to 300 mg, the treatment–
success rate has not been improved in Japan. Global Health
Observatory Data reported that smear-positive tuberculosis
treatment-success rates were 52 % in Japan and 69–95 % in
Europe in 2009 [1]. The lower success rate in the Japanese
population might be explained by an interethnic difference
in NAT2 genotype frequencies. The frequency of rapid ace-
tylator genotypes in the Japanese population (approx. 50 %)
is much higher than that in Caucasians (approx. 5 %) [12,
18, 35, 36]. Taken together, the dose of INH used in con-
ventional treatment is insufficient for more than a third of
Japanese with NAT2*4/*4 in achieving a satisfactory
treatment-success rate. NAT2 genotype-guided dosing strat-
ification would improve early treatment success rates
against tuberculosis, especially in highly-positive excretion
levels of bacilli, if the high dose of INH was applied from
the first prescription exclusively to rapid acetylators.
In conclusion, the present pharmacogenetics clinical trial
with a PROBE-design demonstrated that NAT2 genotype-
guided dosing stratification of INH could improve treatment
outcomes in patients with drug-sensitive tuberculosis. Half
of the conventional standard dose for slow acetylators re-
duced INH-DILI and did not reduce therapeutic efficacy.
For rapid acetylators, 1.5 times the conventional standard
dose of INH reduced early treatment failures without an
increase in the incidence of INH-DILI. We propose here
that the pharmacotherapy against tuberculosis with INH
should be individually designed by stratification based on
Eur J Clin Pharmacol (2013) 69:1091–1101 1099
NAT2 genetic information in order to achieve the greatest
success outcome for each patient.
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